MEI Pharma Inc

+0.06 (+2.19%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)323.56M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$10.56 Million
Adjusted EPS-$0.13
See more estimates
10-Day MA$2.85
50-Day MA$2.81
200-Day MA$3.13
See more pivots

MEI Pharma Inc Stock, NASDAQ:MEIP

11455 El Camino Real, Suite 250, San Diego, California 92130
United States of America
Phone: +1.858.369.7100
Number of Employees: 76


MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.